Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 3
Submit an article Journal homepage
503
Views
25
CrossRef citations to date
0
Altmetric
Perspective

Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA

Patricia Vella Bonannoa Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UKView further author information
,
Anna Bucsicsb Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA), Brussels, BelgiumView further author information
,
Steven Simoensc KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, BelgiumView further author information
,
Antony P Martind Health Economics Centre, University of Liverpool Management School, Liverpool, UKView further author information
,
Wija Oortwijne Department for Health Evidence, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Jolanta Gulbinovičf Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, VilniusUniversity, Vilnius, LithuaniaView further author information
,
Celia Rotheg Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, PolandView further author information
,
Angela Timoneya Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;h NHS Lothian, Edinburgh, UKView further author information
,
Alessandra Ferrarioi Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USAView further author information
,
Mohamed Gadj Global Health and Development Group, Imperial College, London, UKView further author information
,
Ahmed Salemk IQVIA, Brussels, BelgiumView further author information
,
Iris Hoxhal Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, AlbaniaView further author information
,
Robert Sauermannm Hauptverband der ÖsterreichischenSozialversicherungsträger, Vienna, AustriaView further author information
,
Maria Kamushevan Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University-Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0002-4379-5283View further author information
ORCID Icon,
Maria Dimitrovan Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University-Sofia, BulgariaView further author information
,
Guenka Petrovan Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University-Sofia, BulgariaView further author information
,
Ott Laiuso State Agency of Medicines, Tartu, EstoniaView further author information
,
Gisbert Selkep Wissenschaftliches Institut der AOK (WidO), Berlin, GermanyView further author information
,
Vasilios Kourafalosq EOPYY-National Organization for the Provision of Healthcare Services, Athens, GreeceView further author information
,
John Yfantopoulosr School of Economics and Political Science, University of Athens, Athens, GreeceORCID Iconhttps://orcid.org/0000-0003-0424-6887View further author information
ORCID Icon,
Einar Magnussons Department of Health Services, Ministry of Health, Reykjavík, IcelandView further author information
,
Roberta Joppit Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, ItalyView further author information
,
Arianit Jakupiu UBT - Higher Education Institute, Prishtina, KosovoView further author information
,
Tomasz Bochenekg Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, PolandView further author information
,
Magdalene Wladysiukv HTA Consulting, Cracow, PolandView further author information
,
Claudia Furtadow Pharmaceutical Division, INFAMED, Lisbon, PortugalView further author information
,
Vanda Marković-Pekovićx Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska, Bosnia and Herzegovina;y Department of Social Pharmacy, University of Banja Luka, Faculty of Medicine, Banja Luka, Republic of Srpska, Bosnia and HerzegovinaView further author information
,
Ileana Mardarez Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, Bucharest, RomaniaView further author information
,
Dmitry Meshkovaa National Research Institution for Public Health, Moscow, RussiaView further author information
,
Jurij Fürstbb Health Insurance Institute, Ljubljana, SloveniaView further author information
,
Dominik Tomekcc Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.View further author information
,
Merce Obach Cortadellasdd Drug Territorial Action Unit, Catalan Health Service, Barcelona, SpainView further author information
,
Corrine Zaradd Drug Territorial Action Unit, Catalan Health Service, Barcelona, SpainView further author information
,
Alan Haycoxd Health Economics Centre, University of Liverpool Management School, Liverpool, UKView further author information
,
Stephen Campbellee Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK;ff NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UKView further author information
&
Brian Godmana Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;d Health Economics Centre, University of Liverpool Management School, Liverpool, UK;gg Division of Clinical Pharmacology, Karolinska, Karolinska Institutet, Stockholm, Sweden;hh Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Garankuwa, South AfricaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6539-6972View further author information
ORCID Icon show all
Pages 251-261 | Received 10 Oct 2018, Accepted 21 Jan 2019, Published online: 15 Feb 2019

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens, Isabelle Huys, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G.M. Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales & Elaine Julian. (2023) The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire. Journal of Market Access & Health Policy 11:1.
Read now
Markus Molitor & Charalabos-Markos Dintsios. (2021) Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 145-157.
Read now
Bertalan Németh, Wim Goettsch, Finn Børlum Kristensen, Oresta Piniazhko, Mirjana Huić, Tomáš Tesař, Dragana Atanasijevic, Iga Lipska & Zoltán Kaló. (2020) The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research 20:4, pages 321-330.
Read now

Articles from other publishers (22)

Meysam Behzadifar, Masoud Behzadifar, Maryam Saran, Saeed Shahabi, Ahad Bakhtiari, Samad Azari & Nicola Luigi Bragazzi. (2023) The role of Iran's context for the development of health technology assessment: challenges and solutions. Health Economics Review 13:1.
Crossref
Rick A. Vreman, Daan van Hoof, Anna Nachtnebel, Joël Daems, Marc van de Casteele, Emer Fogarty, Roisin Adams & Lonneke Timmers. (2023) The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries’ past health technology assessments. International Journal of Technology Assessment in Health Care 39:1.
Crossref
Rebecca Trowman, Antonio Migliore & Daniel A. Ollendorf. (2023) Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment. International Journal of Technology Assessment in Health Care 39:1.
Crossref
T. Gophika, S. Sudha & M. R. Ranjana. 2023. Translating Healthcare Through Intelligent Computational Methods. Translating Healthcare Through Intelligent Computational Methods 3 17 .
Michael F. Drummond, Federico Augustovski, Devarshi Bhattacharyya, Jonathan Campbell, Nathorn Chaiyakanapruk, Yingyao Chen, Rosa Maria Galindo-Suarez, John Guerino, Aurelio Mejía, Michelle Mujoomdar, Daniel Ollendorf, Naoko Ronquest, Aleksandra Torbica, Emily Tsiao, John Watkins & Kai Yeung. (2022) Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report. Value in Health 25:8, pages 1257-1267.
Crossref
Alice Pisana, Björn Wettermark, Amanj Kurdi, Biljana Tubic, Caridad Pontes, Corinne Zara, Eric Van Ganse, Guenka Petrova, Ileana Mardare, Jurij Fürst, Marta Roig-Izquierdo, Oyvind Melien, Patricia Vella Bonanno, Rita Banzi, Vanda Marković-Peković, Zornitsa Mitkova & Brian Godman. (2022) Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. Frontiers in Pharmacology 13.
Crossref
Jason Gordon, Angela Stainthorpe, Beverley Jones, Ian Jacob, Nadine Hertel, Jose Diaz, Yong Yuan & John Borrill. (2021) Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making. PharmacoEconomics - Open 5:4, pages 701-713.
Crossref
Patricia Vella Bonanno, Vincent Cassar & Brian Godman. (2021) A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges. Frontiers in Pharmacology 12.
Crossref
Ramon Schaefer, Diego Hernandez, Lorenz Selberg & Michael Schlander. (2021) Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?. Journal of Comparative Effectiveness Research 10:16, pages 1187-1195.
Crossref
Luka Vončina, Tea Strbad, Jurij Fürst, Maria Dimitrova, Maria Kamusheva, Megi Vila, Ileana Mardare, Kristina Hristova, Andras Harsanyi, Dragana Atanasijević, Igor Banović & Ana Bobinac. (2021) Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. Applied Health Economics and Health Policy 19:6, pages 915-927.
Crossref
Bettina M. Zimmermann, Johanna Eichinger & Matthias R. Baumgartner. (2021) A systematic review of moral reasons on orphan drug reimbursement. Orphanet Journal of Rare Diseases 16:1.
Crossref
Ani Matei, Adrian-Stelian Dumitru & Corina-Georgiana Antonovici. (2021) The EU Health Technology Assessment and the Open Method of Coordination: A Relation with Potential in the Context of Network Governance. Sustainability 13:6, pages 3582.
Crossref
Dominik J. Wettstein & Stefan Boes. (2021) Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept. BMC Health Services Research 21:1.
Crossref
Olga Löblová. (2021) Health Technology Assessment and Health Care Reimbursement in the European Union: Permissive Dissensus and the Limits of Harmonization through the Backdoor. Journal of Health Politics, Policy and Law 46:1, pages 117-145.
Crossref
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett & Arnold G. Vulto. (2021) The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology 11.
Crossref
Patricia Vella Bonanno, Alec Morton & Brian Godman. 2021. Expert Judgement in Risk and Decision Analysis. Expert Judgement in Risk and Decision Analysis 419 439 .
Mohamed Gad, Ahmed Salem, Wija Oortwijn, Ruaraidh Hill & Brian Godman. (2020) Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions. Frontiers in Pharmacology 11.
Crossref
Caridad Pontes, Corinne Zara, Josep Torrent-Farnell, Merce Obach, Cristina Nadal, Patricia Vella-Bonanno, Michael Ermisch, Steven Simoens, Renata Curi Hauegen, Jolanta Gulbinovic, Angela Timoney, Antony P. Martin, Tanja Mueller, Anna Nachtnebel, Stephen Campbell, Gisbert Selke, Tomasz Bochenek, Celia C. Rothe, Ileana Mardare, Marion Bennie, Jurij Fürst, Rickard E. Malmstrom & Brian Godman. (2019) Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Applied Health Economics and Health Policy 18:1, pages 5-16.
Crossref
Livio Garattini & Anna Padula. (2019) HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?. The European Journal of Health Economics 21:1, pages 1-5.
Crossref
Marcin Czech, Aleksandra Baran-Kooiker, Kagan Atikeler, Maria Demirtshyan, Kamilla Gaitova, Malwina Holownia-Voloskova, Adina Turcu-Stiolica, Coen Kooiker, Oresta Piniazhko, Natella Konstandyan, Olha Zalis'ka & Jolanta Sykut-Cegielska. (2020) A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries. Frontiers in Public Health 7.
Crossref
Anna Padula & Livio Garattini. (2019) Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?. Journal of the Royal Society of Medicine 113:1, pages 12-15.
Crossref
Alexander B. Nolsøe, Peter B. Østergren, Christian Fuglesang S. Jensen & Mikkel Fode. (2019) From separation to collaboration: the future of urology. Nature Reviews Urology 16:11, pages 633-634.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.